Global Chronic Kidney Disease Market Overview
Chronic Kidney Disease Market Size was valued at USD 38.36 Billion in 2023. The Global Chronic Kidney Disease industry is projected to grow from USD 40.53 Billion in 2024 to USD 63.52 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.78% during the forecast period (2024 - 2032).
The increasing prevalence of kidney diseases, the increasing number of biopsy procedures, and the rising demand for new techniques for diagnosis of chronic diseases are driving the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
September 2023: AWAK Technologies (AWAK), an innovative medical technology company that treats end-stage renal disease via dialysis utilizing regeneration technology, announced, that it has raised more than $20 million in Series B funding. This accomplishment not only represents the most substantial fundraising endeavor undertaken by MedTech to date, but also ranks among the most substantial in Southeast Asia as of this moment. The round was co-led by venture capital firms Lion X Ventures and Vickers Venture Partners, Advanced MedTech, Eckuity Capital, a United States-based healthcare venture capital fund, and an investment office specializing in the management of multibillion-dollar assets within the healthcare industry. AWAK PD, an ultraportable and wearable peritoneal dialysis (PD) system, offers patients the convenience of conducting dialysis at their residences or while on the move. This solution effectively tackles a prevalent challenge encountered by patients requiring dialysis at present: extended periods of stationary therapy and reliance on cumbersome connections to dialysis machines located in hospitals and clinics.
April 2023: Medtronic, a manufacturer of medical devices, and DaVita formed Mozarc Medical, a corporation committed to the development of renal care technologies, focusing specifically on at-home remedies. The fact that Medtronic and DaVita each own an equal equity stake in the company was made public nearly a year ago. It was confirmed by executives from both DaVita and Medtronic that the two organizations provided an initial funding of $200 million in cash for the establishment of the company. The corporations shall contribute future operating capital to ensure the organization's continued operations. Mozarc will be governed by a six-member board of directors, of which two will be appointed from each company and two will be independent directors. According to the companies, Mozarc Medical will expand the capacity of dialysis delivery systems and other technologies utilized in the treatment of advanced phases of kidney disease by leveraging DaVita's expertise in dialysis services and Medtronic's proficiency in medical devices.
Kidney illness, and the rising number of biopsy operations are all factors fueling the market. Increases in governmental spending and the development of more sensitive diagnostic tools for identifying CKD at an early stage are further factors that should drive the market forward.
The chronic kidney disease (CKD) market is expected to increase because of factors such as the increasing popularity of transplantation therapy and the presence of a sizable elderly population. The high level of R&D activity in the expansion of CKD medications and the favorable reimbursement policies in emerging nations are also expected to drive the market growth rate. Market growth for chronic kidney disease (CKD) is also predicted to be influenced by the focus of various manufacturers on innovation and technological breakthroughs in treatment.
The prevalence of CKD is high and rising in many regions of the world, which is expected to boost demand for blood testing. End-stage renal disease (ESRD) is extremely common and rapidly increasing in prevalence around the world. As a result, it opens up new avenues for business expansion.In July, 2023, Recent work by a team at the University of Edinburgh sheds light on a protein associated to kidney and heart damage, which may lead to new approaches to treating chronic kidney disease. Researchers have found that the protein Indian Hedgehog (IHH) promotes scarring in the kidneys and hearts of mice. Damaged or aging kidneys manufacture and release this protein from certain cells. Chronic kidney disease (CKD) affects 10% of the global population, and experts say further research is needed to investigate IHH as a possible target for medicines to treat CKD.
Chronic Kidney Disease Market Trends
- The increasing prevalence of kidney diseases to boost the market growth
The worldwide rise in the prevalence and incidence of obesity is the main factor driving the growth of the chronic kidney disease device market. For instance, the World Health Organization estimated that over 1 billion people worldwide 650 million adults, 340 million adolescents, and 39 million children are obese as of March 2022. Additionally, by 2025, 167 million people and children who are overweight or obese will also have worse health overall. As a result of the rising obesity rate, more people are anticipated to seek out chronic kidney disease during the forecast period.
Furthermore, Additionally, according to data from the American Cancer Society for 2022, there are projected to be about 79,000 new cases of kidney cancer in the country that year (50,290 men and 28,710 women). The lifetime chance of developing kidney cancer is higher in males (2.02%) than in women (1.03%), according to the same source. This is expected to spur market expansion over the coming years.
Chronic Kidney Disease Market Segment Insights
Chronic Kidney Disease Diagnosis Insights
The chronic kidney disease market segmentation, based on diagnosis, includes blood test, urine test, imaging test, and kidney biopsy. The blood tests segment is to hold the majority share in 2022 in the chronic kidney disease market revenue. This is due to rising burden of chronic kidney disease and expanding technologically advanced diagnostic products. In addition, the major test for the diagnosis of renal disease combines a blood test and aids in determining how well the kidneys are functioning. The blood test measures blood amounts of a secondary effect known as creatinine.
May 2021: FDA approved Farxiga by AstraZeneca for treating chronic kidney disease (CKD) in people with and without type-2 diabetes who are at risk of progression.
Figure 2: Chronic Kidney Disease Market, By Diagnosis, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Chronic Kidney Disease Treatment Insights
The chronic kidney disease market segmentation, based on Treatment, includes drugs, dialysis, and kidney transplant. The drugs segment is to hold the majority share in 2022 in the chronic kidney disease market revenue. This is due to increased government support for research and development, and the availability of funding for research contributions. Furthermore, A growing focus on the development of new drugs increased government support for research and development, and the availability of funding for research contributions.
Chronic Kidney Disease Indication Insights
The chronic kidney disease market segmentation, based on indication, includes Type 1 Or type 2 diabetes, high blood pressure, and polycystic kidney disease. The Type 1 or type 2 diabetes segment is to hold the majority share in 2022 in the chronic kidney disease market revenue. This is due to rising prevalence of diabetes, rising prevalence of obesity, changing lifestyles, and new product approvals, as well as those factors, as well as rising prevalence of diabetes, rising prevalence of obesity, and changing lifestyle. In addition, according to the CDC, in 2018, 34.2 million people in the US, or 10.5% of the US population, had diabetes. Of these 34.2 million adults with diabetes, 26.8 million were diagnosed with diabetes, while 7.3 million people were still undiagnosed. Also, the proportion of undiagnosed diabetes was 30%-40% in Europe in 2019.
Chronic Kidney Disease End User Insights
The chronic kidney disease market segmentation is based on end-user that includes hospital & clinics and diagnostic centers. The hospital & clinics segment has dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. This is due to the availability of advanced technological devices and the increase in diabetes and chronic kidney disease decreases, the increasing number weekly dialysis in the hospitals and clinics, together with the development of wellness trends, particularly in developed countries.
In July, 2023,The National Institutes of Health (NIH) funded a collaborative project between the University of California (UC) San Diego, Washington University, and other institutions to develop an atlas tool to facilitate treatment for kidney illness by study of cells and nuclei. It can be challenging to evaluate and investigate treatments for renal problems due to the complexity of the kidney organ. However, a fresh method has been taken in the Kidney Tissue Atlas. KPMP's goal is to improve treatment for chronic kidney disease and acute kidney injury (AKI) by investigating the strong possibility that both conditions have distinct origins. Educating yourself on the various illness mechanisms and their causes will help you treat the condition more effectively.Jardiance (empagliflozin), manufactured by Eli Lilly and Boehringer Ingelheim, was authorized by the European Commission (EC) on July 20, 2023, for the treatment of adults with chronic kidney disease (CKD). Patients with type 2 diabetes and cardiovascular disease are the first to have mortality reduction data included in the label for the oral, once-daily, highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor. Over 47 million people in the EU suffer from CKD, and the approval of empagliflozin by the EC has the potential to improve their quality of life. Patients with CKD will have a lower chance of being hospitalized for any reason.
Chronic Kidney Disease Regional Insights
By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America chronic kidney disease market is expected to be the fastest growing during the study period. This is attributed to the rising prevalence of chronic kidney diseases, the presence of well-established healthcare infrastructure along with high health spending, and technologically advanced diagnostic tests in the region. Moreover, the primary reason fueling the market's expansion is the rising prevalence of chronic kidney diseases in the population. For instance, according to a study released in February 2022 by the American Kidney Fund, 92,000 Americans are waiting for kidney transplants and an estimated 37 million Americans have kidney disease. Therefore, the rising rates of chronic renal disease, a developed healthcare system, high health spending, and technologically sophisticated diagnostic procedures are the main drivers of market expansion.
Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: Chronic Kidney Disease Market Share By Region, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe chronic kidney disease market is expected to account for the second-largest market share due to the increasing incidences of chronic kidney diseases and growth in government expenditure in the healthcare sector in the region. Further, the Germany chronic kidney disease market is expected to hold 3rd place for the market share, and the UK chronic kidney disease market is expected to fastest-growing market, and which is in the 4th place in the European region. Furthermore, France chronic kidney disease market will hold the 5th place for the market share.
The Asia-Pacific chronic kidney disease market is expected to grow at a high CAGR from 2024 to 2032. This is due to the due to the increasing incidences of end-stage diseases and high development in government expenditure in the healthcare industry in the Asia-Pacific region. Moreover, India chronic kidney disease market is expected to hold the largest market share, and China chronic kidney disease market is expected fastest-growing market in the Asia-Pacific region.
Furthermore, India is considered as one of the countries with the highest growth rates in the healthcare sector. Due to an increase in life expectancy and illnesses brought on by a sedentary lifestyle is considerably increasing which will fuel the growth for the chronic kidney disease market.
The Rest of the World includes the Middle East, Africa, and Latin America. This segment is projected to hold the least share in the chronic kidney disease market. In this region, the Middle East is anticipated to dominate owing to the as rising prevalence of diabetes resulting in renal diseases and rising incidences of renal diseases in the region. Furthermore, growing funding and participation from the public and private sectors in R&D initiatives, as well as advancements in the infrastructure of the area, encourage market growth.
Chronic Kidney Disease Key Market Players & Competitive Insights
The chronic kidney disease market is characterized by the presence of many global, regional, and local vendors catering to the demand created by research scientists and pharmaceutical and biotechnology companies operating in the industry. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios. Companies such as Abbott (US), Siemens (Germany), Beckman Coulter (US), and F. Hoffmann-La Roche Ltd (Switzerland) the chronic kidney disease market due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are focused on investing in research and development. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.
One of the primary business strategies adopted by manufacturers in the chronic kidney disease industry to benefit clients and expand the chronic kidney disease market sector is to manufacture locally to reduce operating costs.
GlaxoSmithKline Plc (UK) is a science-led healthcare company that researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines, and consumer healthcare. It is one of the few healthcare companies researching both medicines and vaccines for the world health organization’s three prime diseases, HIV/Aids, tuberculosis, meningococcal, and malaria. The company has also developed some of the leading medicines in these fields. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals, and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa, and the Middle East. For instance, in June 2020, GlaxoSmithKline Plc (UK) received regulatory approval for Duvroq (daprodustat) in Japan for patients with anemia due to chronic kidney disease.
Also, F. Hoffmann-La Roche Ltd (Roche) develops & markets products for diagnosis & treatment of anemia, cancer, anticoagulation therapy, cardiovascular diseases, diabetes, central nervous system, chlamydia, dermatology, gonorrhea, gout, hepatitis B and C, hemostasis disorders, HIV/AIDS, HPV, infectious diseases, and autoimmune diseases. The company specializes in the field of molecular diagnostics & medicines for oncology, virology, inflammation, metabolism, central nervous system (CNS), clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology. The firm operates in two major business segments, namely, pharmaceuticals and diagnostics. The company has strong presence in North America, Europe, Asia, and the Middle East.
Key Companies in the Chronic Kidney Disease Market include
- Abbott (US)
- Siemens (Germany)
- Beckman Coulter (US)
- F. Hoffmann-La Roche Ltd (Switzerland)
- ACON Laboratories, Inc (US)
- Nova Biomedical (US)
- ARKRAY (Japan)
- AstraZeneca (UK)
- GlaxoSmithKline Plc (UK)
- Bayer AG (Germany)
Chronic Kidney Disease Industry Developments
November 2023: Sun Pharma to co-market Zydus Lifesciences' drug for Chronic Kidney Disease (CKD)Bayer launches pill to treat chronic kidney disease linked to diabetes.
October 2023: Medtronic launches clinical trial to evaluate the safety and efficacy of its new renal denervation catheter for the treatment of CKDAstraZeneca's Farxiga approved in the US for the treatment of CKD.
September 2023: Fresenius Medical Care receives FDA breakthrough device designation for its latest hemodialysis machineBoehringer Ingelheim and Eli Lilly announce new clinical trials for their oral SGLT2 inhibitor for CKD.
August 2023: Novartis launches new global initiative to raise awareness of CKD and improve access to careDaVita Kidney Care partners with Verily to develop new digital health tools for people with CKD.
July 2023: Otsuka Pharmaceutical and Bristol Myers Squibb announce new clinical trials for their oral HIF-2α inhibitor for CKD AstraZeneca and Silence Therapeutics announce new clinical trials for their siRNA therapy for CKD.
Chronic Kidney Disease Market Segmentation
Chronic Kidney Disease Diagnosis Outlook
- Blood Test
- Urine Test
- Imaging Test
- Kidney Biopsy
Chronic Kidney Disease Treatment Outlook
- Drugs
- Dialysis
- Kidney Transplant
Chronic Kidney Disease Indication Outlook
Chronic Kidney Disease End User Outlook
- Hospital & Clinics
- Diagnostic Centers
Chronic Kidney Disease Regional Outlook
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
| Report Attribute/Metric |
Details |
| Market Size 2023 |
USD 38.36 billion |
| Market Size 2024 |
USD 40.53 billion |
| Market Size 2032 |
USD 63.52 billion |
| Compound Annual Growth Rate (CAGR) |
5.78% (2024-2032) |
| Base Year |
2023 |
| Forecast Period |
2024-2032 |
| Historical Data |
2019 & 2022 |
| Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Diagnosis, Treatment, Indication, End User, And Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered |
The U.S, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled |
Abbott (US), Siemens (Germany), Beckman Coulter (US), F. Hoffmann-La Roche Ltd (Switzerland), ACON Laboratories, Inc (US), Nova Biomedical (US), ARKRAY (Japan), AstraZeneca (UK), GlaxoSmithKline Plc (UK), and Bayer AG (Germany) |
| Key Market Opportunities |
New techniques for diagnosis of chronic kidney disease |
| Key Market Dynamics |
Increasing prevalence of kidney diseases Increasing number of biopsy procedures Rising demand for new techniques for diagnosis of chronic diseases. |
Chronic Kidney Disease Market Highlights:
Frequently Asked Questions (FAQ) :
The chronic kidney disease market is anticipated to reach USD 63.52 billion at a CAGR of 5.78% during the forecast period of 2024 to 2032.
The U.S. chronic kidney disease market is anticipated to reach USD 27.37-36.53 billion during the forecast period of 2024 to 2032.
The chronic kidney disease market is expected to register a CAGR of 5.78% during the forecast period of 2024 to 2032.
The North America chronic kidney disease market accounted for the largest share in the chronic kidney disease market.
Abbott (US), Siemens (Germany), Beckman Coulter (US), F. Hoffmann-La Roche Ltd (Switzerland), ACON Laboratories, Inc (US), Nova Biomedical (US), ARKRAY (Japan), AstraZeneca (UK), GlaxoSmithKline Plc (UK), and Bayer AG (Germany).
The Type 1 or Type 2 diabetes segment held the majority share in 2021 contributing to around 10.09% with respect to the chronic kidney disease market.
The hospital & clinics segment dominated the market in 2023 and is projected to be the fastest-growing segment during the forecast period, 2024-2032.
